NUCLEARPOTENCY

Nuclear foundations of cellular potency

Coordinatore	CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	France [FR]
Totale costo	1˙496˙000 €
EC contributo	1˙496˙000 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2011-StG_20101109
Funding Scheme	ERC-SG
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-02-01   -   2017-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE  Organization address address: Rue Laurent Fries 1 city: ILLKIRCH GRAFFENSTADEN postcode: 67404 contact info Titolo: Dr. Nome: Maria-Elena Cognome: Torres-Padilla Email: send email Telefono: +33 3 88 65 33 60 Fax: +33 3 88 65 32 03	FR (ILLKIRCH GRAFFENSTADEN)	hostInstitution	1˙496˙000.00
2	CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE  Organization address address: Rue Laurent Fries 1 city: ILLKIRCH GRAFFENSTADEN postcode: 67404 contact info Titolo: Dr. Nome: Steve Cognome: Brooks Email: send email Telefono: +33 3 88 65 33 94 Fax: +33 3 88 65 32 03	FR (ILLKIRCH GRAFFENSTADEN)	hostInstitution	1˙496˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'A fundamental question in biology is to understand the mechanisms underlying cell plasticity. Such plasticity or potency is essential to form multiple cell types upon differentiation. In mammals, upon fertilization and fusion of the gametes –two highly differentiated cells- intense chromatin remodeling and epigenetic reprogramming, the reversion into an undifferentiated state, are essential to restore full developmental potency (totipotency). Subsequent development and differentiation are accompanied with progressive loss of plasticity. The transition between totipotency and the gradual loss of plasticity is thought to be regulated by yet-unknown epigenetic mechanisms.

The embryonic chromatin displays unique features compared to differentiated cells, including the lack of ‘conventional’ heterochromatin. We hypothesise that the transition from a totipotent state to a differentiated one is regulated by changes in chromatin states, particularly by de novo acquisition of heterochromatin domains.

This project is designed to reveal the nuclear foundations of totipotency by determining the molecular mechanisms underlying the establishment of heterochromatin and their functional role in maintaining totipotency using the mouse embryo as model.

We will do this by: i)determining the functional relationship of heterochromatin and nuclear architecture ii)by determining the effects of artificially inducing heterochromatin on cell potency during development and iii)by determining the mechanisms that regulate heterochromatin formation in the embryo.

We anticipate that our studies will unravel fundamental mechanims on how chromatin states regulate cell potency during reprogramming. By uncovering such mechanisms, we expect to reveal new insights that will be useful to induce epigenetic reprogramming of differentiated cells. Our results will therefore lead to key contributions in the fields of stem cell, developmental biology, human reproduction, chromatin biology and epigenetics.'